Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ASHOK PATEL

NPI
1093809576
CMS profile
276954
Location
TOMS RIVER, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$6,054.38

18 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $5,182.40 1
Travel and Lodging $475.53 4
Food and Beverage $396.45 13

By paying entity

PY2022 · entire year · sorted by reported total

Page 1 of 1; records 1–18 of 18 matching records. This page contains 18 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ASHOK PATEL

NPI 1093809576 · CMS profile ID 276954

TOMS RIVER, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–18 of 18 matching records. This page contains 18 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1093809576?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ASHOK PATEL, NPI 1093809576, CMS profile ID 276954. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–18 of 18 matching records. This page contains 18 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1093809576?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). ASHOK PATEL, NPI 1093809576, CMS profile ID 276954. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–18 of 18 matching records. This page contains 18 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1093809576?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
ASHOK PATEL, NPI 1093809576, CMS profile ID 276954, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–18 of 18 matching records. This page contains 18 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1093809576?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

18 matching records · $6,054.38 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 18 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–18 of 18.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Otsuka America Pharmaceutical, Inc. $41.2512/15/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929323713 CMS
Otsuka America Pharmaceutical, Inc. $42.5612/15/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929323715 CMS
Otsuka America Pharmaceutical, Inc. $15.7312/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929323709 CMS
Otsuka America Pharmaceutical, Inc. $130.0012/12/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929323711 CMS
Takeda Pharmaceuticals U.S.A., Inc. $15.8212/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 956219573 CMS
Otsuka America Pharmaceutical, Inc. $5,182.4012/06/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929323707 CMS
Otsuka America Pharmaceutical, Inc. $49.9911/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929323701 CMS
Otsuka America Pharmaceutical, Inc. $49.9711/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929323703 CMS
Otsuka America Pharmaceutical, Inc. $36.3311/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929323705 CMS
ABBVIE INC. $13.1211/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891324863 CMS
Otsuka America Pharmaceutical, Inc. $261.7211/10/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929323697 CMS
Otsuka America Pharmaceutical, Inc. $110.5711/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929323699 CMS
Lilly USA, LLC $15.4709/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 917892723 CMS
ABBVIE INC. $12.4008/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891324861 CMS
Otsuka Pharmaceutical Development & Commercialization, Inc. $34.0006/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 933757417 CMS
Biohaven Pharmaceutical Holding Company Ltd. $14.8305/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923696211 CMS
Biohaven Pharmaceutical Holding Company Ltd. $14.6303/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923696209 CMS
Lilly USA, LLC $13.5903/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 917889167 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,320.42 66
PY2020 $2,969.84 33
PY2021 $7,553.27 35
PY2022 $6,054.38 18
PY2023 $14,560.76 55
PY2024 $22,723.92 31
PY2025 $6,910.62 19

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $2,752.51 11
PY2025 Principal investigator $1,229,009.00 130
PY2024 Principal investigator $3,194,861.98 28
PY2023 Recipient $355.00 1
PY2023 Principal investigator $1,914,939.19 59
PY2022 Recipient $1,248.00 4
PY2022 Principal investigator $1,105,512.02 75
PY2021 Recipient $13,374.00 3
PY2021 Principal investigator $1,695,784.21 81
PY2020 Recipient $6,288.97 21
PY2020 Principal investigator $1,118,610.73 104
PY2019 Recipient $18,854.85 12
PY2019 Principal investigator $1,138,230.38 171

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

79 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,160.25 12/31/2022 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH INC
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine No dispute reported 06/30/2026 889827805
Principal investigator 1 ABBVIE INC. $462.42 12/31/2022 Non-covered Recipient Entity
CONQUEST RESEARCH
A Study to Evaluate Efficacy and Safety of Upadacitinib in Adult Participants With Axial Spondyloarthritis (SELECT AXIS 2) No dispute reported 06/30/2026 965540053
Principal investigator 1 ABBVIE INC. $77.25 12/31/2022 Non-covered Recipient Entity
KANSAS INSTITUTE OF RESEARCH
Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants No dispute reported 06/30/2026 965540243
Principal investigator 1 ITI, Inc. $20,345.11 12/23/2022 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 952369363
Principal investigator 1 ITI, Inc. $11,184.53 12/23/2022 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH PC
AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 952369371
Principal investigator 1 ABBVIE INC. $24,747.05 12/07/2022 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine No dispute reported 06/30/2026 889823423
Principal investigator 1 ITI, Inc. $400.00 12/02/2022 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 952369209
Principal investigator 1 ITI, Inc. $450.00 12/02/2022 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH PC
AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 952369211
Principal investigator 1 ITI, Inc. $7,708.14 11/25/2022 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 952369107
Principal investigator 1 ITI, Inc. $17,036.69 11/25/2022 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH PC
AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 952369117
Principal investigator 1 Eisai Inc. $5,338.87 11/22/2022 Non-covered Recipient Entity
Bio-Behavioral Health
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926005615
Principal investigator 1 Eisai Inc. $9,049.50 11/22/2022 Non-covered Recipient Entity
Bio-Behavioral Health
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926005619
Principal investigator 1 ABBVIE INC. $34,161.75 11/08/2022 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine No dispute reported 06/30/2026 889818715
Principal investigator 1 Eisai Inc. $70,811.10 11/08/2022 Non-covered Recipient Entity
Bio-Behavioral Health
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926005617
Principal investigator 1 ITI, Inc. $16,318.06 10/28/2022 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 952368879
Principal investigator 1 ITI, Inc. $16,415.27 10/28/2022 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH PC
AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 952368887
Principal investigator 1 ITI, Inc. $180.00 10/21/2022 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH PC
AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 952368873
Principal investigator 1 ABBVIE INC. $27,869.04 10/11/2022 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine No dispute reported 06/30/2026 889814147
Principal investigator 1 ITI, Inc. $5,196.59 09/30/2022 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 952368721
Principal investigator 1 ITI, Inc. $16,071.31 09/30/2022 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH PC
AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 952368727
Principal investigator 1 ABBVIE INC. $22,958.25 09/08/2022 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine No dispute reported 06/30/2026 889809435
Principal investigator 1 ITI, Inc. $10,070.16 09/02/2022 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 952368507
Principal investigator 1 ITI, Inc. $22,729.81 09/02/2022 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH PC
AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 952368541
Principal investigator 1 ABBVIE INC. $24,329.84 08/05/2022 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine No dispute reported 06/30/2026 889803681
Principal investigator 1 ITI, Inc. $474.00 08/05/2022 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 952368357
Principal investigator 1 ITI, Inc. $26,024.77 08/02/2022 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 952368255
Principal investigator 1 ITI, Inc. $11,354.58 08/02/2022 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH PC
AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 952368269
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $7,618.00 07/11/2022 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A randomized double-blind placebo-controlled trial of adjunctive Troriluzole in Obsessive Compulsive Disorder No dispute reported 06/30/2026 933392745
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $3,929.20 07/11/2022 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A randomized double-blind placebo-controlled trial of adjunctive Troriluzole in Obsessive Compulsive Disorder No dispute reported 06/30/2026 933392753
Principal investigator 1 ITI, Inc. $711.00 07/05/2022 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 952368087
Principal investigator 1 ABBVIE INC. $18,144.55 07/01/2022 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine No dispute reported 06/30/2026 889798027
Principal investigator 1 Eli Lilly and Company $4,200.00 07/01/2022 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREATMENT OF MIGRAINE PIONEER PEDS1 No dispute reported 06/30/2026 917821909
Principal investigator 1 ITI, Inc. $21,937.38 06/24/2022 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 952367995
Principal investigator 1 ITI, Inc. $12,885.91 06/24/2022 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH PC
AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 952368011
Principal investigator 1 ABBVIE INC. $47.97 06/23/2022 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine No dispute reported 06/30/2026 889797073
Principal investigator 1 ABBVIE INC. $3,628.91 06/21/2022 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine No dispute reported 06/30/2026 889796551
Principal investigator 1 ITI, Inc. $711.00 06/17/2022 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 952367853
Principal investigator 1 ITI, Inc. $711.00 06/03/2022 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH PC
AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 952367789
Principal investigator 1 ITI, Inc. $22,305.64 05/31/2022 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 952367733
Principal investigator 1 ITI, Inc. $6,224.10 05/31/2022 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH PC
AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 952367743
Principal investigator 1 Eli Lilly and Company $9,763.00 05/09/2022 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF GALCANEZUMAB IN PATIENTS 6 TO 17 YEARS OF AGE WITH EPISODIC MIGRAINE - THE REBUILD STUDY No dispute reported 06/30/2026 917821905
Principal investigator 1 ABBVIE INC. $10,500.00 05/04/2022 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine No dispute reported 06/30/2026 889789555
Principal investigator 1 ITI, Inc. $12,586.50 05/03/2022 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 952367449
Principal investigator 1 ITI, Inc. $3,126.30 05/03/2022 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH PC
AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 952367459
Recipient Eli Lilly and Company $570.00 04/29/2022 Covered Recipient Physician A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY3451838 IN ADULTS WITH TREATMENT-RESISTANT MIGRAINE No dispute reported 06/30/2026 917806451
Recipient Eli Lilly and Company $529.00 04/29/2022 Covered Recipient Physician ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 917806457
Recipient Eli Lilly and Company $50.00 04/29/2022 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF GALCANEZUMAB IN PATIENTS 6 TO 17 YEARS OF AGE WITH EPISODIC MIGRAINE - THE REBUILD STUDY No dispute reported 06/30/2026 917808715
Recipient Eli Lilly and Company $99.00 04/29/2022 Covered Recipient Physician PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREATMENT OF MIGRAINE PIONEER PEDS1 No dispute reported 06/30/2026 917811335
Principal investigator 1 ITI, Inc. $6,058.34 04/15/2022 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 952367423
Principal investigator 1 ITI, Inc. $6,705.85 03/25/2022 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 952367323
Principal investigator 1 ITI, Inc. $1,275.19 03/25/2022 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH PC
AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 952367333
Principal investigator 1 Eisai Inc. $11,744.14 03/21/2022 Non-covered Recipient Entity
Bio-Behavioral Health
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926005613
Principal investigator 1 Allergan, Inc. $7,944.60 03/08/2022 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 864374189
Principal investigator 1 ITI, Inc. $17,080.38 02/25/2022 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 952367165
Principal investigator 1 ITI, Inc. $7,028.42 02/25/2022 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH PC
AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 952367169
Principal investigator 1 Eisai Inc. $14,068.00 02/21/2022 Non-covered Recipient Entity
Bio-Behavioral Health
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926005611
Principal investigator 1 Allergan, Inc. $11,062.75 02/17/2022 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 864370547
Principal investigator 1 Eli Lilly and Company $62,560.00 02/16/2022 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY3451838 IN ADULTS WITH TREATMENT-RESISTANT MIGRAINE No dispute reported 06/30/2026 917822079
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $11,615.50 02/08/2022 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A randomized double-blind placebo-controlled trial of adjunctive Troriluzole in Obsessive Compulsive Disorder No dispute reported 06/30/2026 933379335
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $8,541.00 02/08/2022 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A randomized double-blind placebo-controlled trial of adjunctive Troriluzole in Obsessive Compulsive Disorder No dispute reported 06/30/2026 933379343
Principal investigator 1 Eli Lilly and Company $149.00 01/31/2022 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREATMENT OF MIGRAINE PIONEER PEDS1 No dispute reported 06/30/2026 917822081
Principal investigator 1 ITI, Inc. $6,863.19 01/28/2022 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 952366917
Principal investigator 1 ITI, Inc. $4,838.00 01/28/2022 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH PC
AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 952366923
Principal investigator 1 Avanir Pharmaceuticals, Inc. $2,179.30 01/26/2022 Non-covered Recipient Entity
VANTAGE CLINICAL TRIALS
18-AVP-786-207 No dispute reported 06/30/2026 937450915
Principal investigator 1 Avanir Pharmaceuticals, Inc. $237.50 01/26/2022 Non-covered Recipient Entity
VANTAGE CLINICAL TRIALS
18-AVP-786-207 No dispute reported 06/30/2026 937450969
Principal investigator 1 Eli Lilly and Company $343.00 01/26/2022 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF GALCANEZUMAB IN PATIENTS 6 TO 17 YEARS OF AGE WITH EPISODIC MIGRAINE - THE REBUILD STUDY No dispute reported 06/30/2026 917821907
Principal investigator 1 Avanir Pharmaceuticals, Inc. $237.50 01/25/2022 Non-covered Recipient Entity
VANTAGE CLINICAL TRIALS
18-AVP-786-207 No dispute reported 06/30/2026 937450959
Principal investigator 1 Avanir Pharmaceuticals, Inc. $1,615.00 01/25/2022 Non-covered Recipient Entity
VANTAGE CLINICAL TRIALS
18-AVP-786-207 No dispute reported 06/30/2026 937450975
Principal investigator 1 Avanir Pharmaceuticals, Inc. $2,337.00 01/25/2022 Non-covered Recipient Entity
VANTAGE CLINICAL TRIALS
18-AVP-786-207 No dispute reported 06/30/2026 937450981
Principal investigator 1 Eisai Inc. $6,385.11 01/25/2022 Non-covered Recipient Entity
Bio-Behavioral Health
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926005609
Principal investigator 1 Eli Lilly and Company $3,733.00 01/20/2022 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 917818549
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $96,353.01 01/19/2022 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF BREXPIPRAZOLE AS ADJUNCTIVE THERAPY IN THE MAINTENANCE TREATMENT OF ADULTS WITH MAJOR DEPRESSIVE DISORDER. No dispute reported 06/30/2026 933760465
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $19,540.74 01/19/2022 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, 12-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 2-ARM, FIXED-DOSE TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF BREXPIPRAZOLE (OPC-34712) IN THE TREATMENT OF SUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA OF THE ALZHEIMERS TYPE No dispute reported 06/30/2026 933760471
Principal investigator 1 ITI, Inc. $237.00 01/14/2022 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 952366791
Principal investigator 1 Allergan, Inc. $3,786.70 01/12/2022 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 864367281
Principal investigator 1 Eli Lilly and Company $3,327.00 01/11/2022 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY3451838 IN ADULTS WITH TREATMENT-RESISTANT MIGRAINE No dispute reported 06/30/2026 917821903
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $5,000.00 01/10/2022 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A randomized double-blind placebo-controlled trial of adjunctive Troriluzole in Obsessive Compulsive Disorder No dispute reported 06/30/2026 933376807
Principal investigator 1 ITI, Inc. $5,000.00 01/07/2022 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 952366771
Principal investigator 1 Eli Lilly and Company $235,711.00 01/04/2022 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 917821817